<p>Deep-pocketed investors have adopted a bullish approach towards Moderna (NASDAQ:MRNA), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in MRNA usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 10 extraordinary options activities for Moderna. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 60% leaning bullish and 30% bearish. Among these notable options, 4 are puts, totaling $442,603, and 6 are calls, amounting to $345,665.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $22.0 to $39.0 for Moderna over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Moderna stands at 1508.67, with a total volume reaching 3,911.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Moderna, situated within the strike price corridor from $22.0 to $39.0, throughout the last 30 days.</p>
<h3>Moderna Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1765821665_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="Options Call Chart" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1765821665_0.png"/></p>

<h3>Significant Options Trades Detected:</h3>
<p></p><table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/20/26</td>
<td>$2.31</td>
<td>$2.13</td>
<td>$2.32</td>
<td>$27.00</td>
<td>$347.9K</td>
<td>292</td>
<td>1.5K</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/21/28</td>
<td>$12.45</td>
<td>$11.9</td>
<td>$11.9</td>
<td>$27.00</td>
<td>$119.0K</td>
<td>458</td>
<td>100</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$6.3</td>
<td>$6.0</td>
<td>$6.3</td>
<td>$28.00</td>
<td>$62.3K</td>
<td>1.2K</td>
<td>51</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/20/26</td>
<td>$1.65</td>
<td>$1.48</td>
<td>$1.55</td>
<td>$35.00</td>
<td>$46.5K</td>
<td>632</td>
<td>303</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/18/26</td>
<td>$6.15</td>
<td>$5.75</td>
<td>$6.15</td>
<td>$32.00</td>
<td>$43.0K</td>
<td>175</td>
<td>70</td>
</tr>
</tbody>
</table><p></p>
<h3>About Moderna</h3>
<p>Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.</p>
<p>After a thorough review of the options trading surrounding Moderna, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Moderna Standing Right Now?</h3>
<ul>
<li>With a volume of 3,654,858, the price of MRNA is up 0.81% at $29.7. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 60 days.</li>
</ul>
<h3>What The Experts Say On Moderna</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $32.8.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access.
* An analyst from RBC Capital has decided to maintain their Sector Perform rating on Moderna, which currently sits at a price target of $25. 
* An analyst from Morgan Stanley persists with their Equal-Weight rating on Moderna, maintaining a target price of $28. 
* Maintaining their stance, an analyst from Leerink Partners continues to hold a Underperform rating for Moderna, targeting a price of $18. 
* In a cautious move, an analyst from Jefferies downgraded its rating to Hold, setting a price target of $30. 
* An analyst from Piper Sandler downgraded its action to Overweight with a price target of $63. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with Benzinga Pro for real-time alerts.</p>

MRNA

<p>Deep-pocketed investors are showing a bullish sentiment towards Moderna (NASDAQ:MRNA), with significant options trading activity detected. Benzinga's options scanner highlighted 10 extraordinary options activities, with 60% bullish and 30% bearish. The price range targeted is $22.0 to $39.0. Moderna's stock is up 0.81% at $29.7. Analysts have mixed ratings, with price targets ranging from $18 to $63. Moderna, a biotech firm, has 35 mRNA development candidates in clinical studies. Next earnings are expected in 60 days.</p>

Moderna Options Trading: A Deep Dive into Market Sentiment